Guilhem Roubaud

Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design

Karim Fizazi, Stéphanie Foulon, Joan Carles et al. · The Lancet · 2022 · 783 citations · Full text

Medicine, Oncology, Urology +17

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

Maha Hussain, Joaquı́n Mateo, Karim Fizazi et al. · New England Journal of Medicine · 2020 · 766 citations · Full text

Medicine, Oncology, Pharmacology +17

Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression

Lucile Vanhersecke, Maxime Brunet, Jean‐Philippe Guégan et al. · Nature Cancer · 2021 · 569 citations · Full text

Life Sciences, Immunology, Oncology +17

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

Kim N., Dana E. Rathkopf, Matthew R. Smith et al. · Journal of Clinical Oncology · 2023 · 319 citations · Full text

Medicine, Oncology, Urology +17

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

Michael J. Morris, Daniel Castellano, Ken Herrmann et al. · The Lancet · 2024 · 258 citations · Full text

Medicine, Oncology, Urology +17